Literature DB >> 7504420

Monoamines in the brain cerebrospinal fluid of facial pain patients.

A J Bouckoms1, W H Sweet, C Poletti, P Lavori, D Carr, W Matson, P Gamache, N Aronin.   

Abstract

The purpose of the study was to assay monoamines in cerebrospinal fluid (CSF) obtained from the trigeminal cistern of 64 patients with intractable facial pain. The CSF was analyzed for homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG), end-product markers of activity for the dopamine, serotonin, and norepinephrine systems, respectively. HVA averaged 121 ng/mL in these facial pain patients, compared to 150 to 550 ng/mL in 10 studies of ventricular brain CSF in assorted psychiatric and pain patients. 5-HIAA averaged 29 to ng/mL in our facial pain patients compared to 60 to 120 ng/mL in nine studies of ventricular brain CSF in assorted psychiatric and neurological patients. Trigeminal cistern CSF MHPG averaged 9 ng/mL, similar to the range of 13 studies of lumbar CSF of assorted psychiatric and pain diagnoses. These results indicate that (1) the electrochemical detection method provides a unique way of accurately measuring nanogram concentrations of multiple monoamines in a little as 0.25 mL of CSF; (2) trigeminal cistern and posterior fossa brain CSF monoamine metabolites reflect a different profile of dopaminergic and serotonergic functioning in these facial pain patients from that previously reported with lumbar CSF measurements of other patients; and (3) trigeminal sensory ganglion or brain dopamine and serotonin systems may be concomitantly dysfunctional in intractable facial pain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 7504420      PMCID: PMC2148620     

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  29 in total

1.  CSF monoamine metabolites in chronic pain.

Authors:  Randal D France; Bruno J Urban; Susan Pelton; Clinton D Kilts; Jau-Shyong Hong; Charles B Nemeroff
Journal:  Pain       Date:  1987-11       Impact factor: 6.961

2.  5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases.

Authors:  G W Ashcroft; T B Crawford; D Eccleston; D F Sharman; E J MacDougall; J B Stanton; J K Binns
Journal:  Lancet       Date:  1966-11-12       Impact factor: 79.321

3.  Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism.

Authors:  C G Gottfries; I Gottfries; B E Roos
Journal:  J Neurochem       Date:  1969-09       Impact factor: 5.372

4.  Substances related to 5-hydroxytryptamine in plasma and in lumbar and ventricular fluids of psychiatric patients.

Authors:  G Curzon; B D Kantamaneni; P Van Boxel; P K Gillman; J R Bartlett; P K Bridges
Journal:  Acta Psychiatr Scand Suppl       Date:  1980

5.  Relationships between CSF levels of endorphins and monoamine metabolites in chronic pain patients.

Authors:  B G Almay; F Johansson; L von Knorring; G Sedvall; L Terenius
Journal:  Psychopharmacology (Berl)       Date:  1980-02       Impact factor: 4.530

Review 6.  Biochemical hypotheses on antidepressant drugs: a guide for clinicians or a toy for pharmacologists?

Authors:  S Garattini; R Samanin
Journal:  Psychol Med       Date:  1988-05       Impact factor: 7.723

7.  Pimozide therapy for trigeminal neuralgia.

Authors:  F Lechin; B van der Dijs; M E Lechin; J Amat; A E Lechin; A Cabrera; F Gómez; E Acosta; L Arocha; S Villa
Journal:  Arch Neurol       Date:  1989-09

8.  5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.

Authors:  B Johansson; B E Roos
Journal:  Life Sci       Date:  1967-07-01       Impact factor: 5.037

9.  Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression.

Authors:  A Roy; D Pickar; J De Jong; F Karoum; M Linnoila
Journal:  Arch Gen Psychiatry       Date:  1988-09

10.  Concentration gradient of CSF monoamine metabolites in children and adolescents.

Authors:  M J Kruesi; S E Swedo; S D Hamburger; W Z Potter; J L Rapoport
Journal:  Biol Psychiatry       Date:  1988-09       Impact factor: 13.382

View more
  6 in total

1.  [Substance P, somatostatin and monoaminergic transmitters in the cerebrospinal fluid of patients with chronic idiopathic trigeminal neuralgia].

Authors:  M Strittmatter; M Grauer; E Isenberg; G Hamann; C Fischer; K H Hoffmann; F Blaes; K Schimrigk
Journal:  Schmerz       Date:  1996-10-28       Impact factor: 1.107

Review 2.  The association of sleep and pain: an update and a path forward.

Authors:  Patrick H Finan; Burel R Goodin; Michael T Smith
Journal:  J Pain       Date:  2013-12       Impact factor: 5.820

Review 3.  The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism.

Authors:  Patrick H Finan; Michael T Smith
Journal:  Sleep Med Rev       Date:  2012-06-29       Impact factor: 11.609

4.  Sex and race differences of cerebrospinal fluid metabolites in healthy individuals.

Authors:  Zackery W Reavis; Nikhil Mirjankar; Srikant Sarangi; Stephen H Boyle; Cynthia M Kuhn; Wayne R Matson; Michael A Babyak; Samantha A Matson; Ilene C Siegler; Rima Kaddurah-Daouk; Edward C Suarez; Redford B Williams; Katherine Grichnik; Mark Stafford-Smith; Anastasia Georgiades
Journal:  Metabolomics       Date:  2021-01-18       Impact factor: 4.290

5.  The interface between inhibition of descending noradrenergic pain control pathways and negative affects in post-traumatic pain patients.

Authors:  Yulong Cui; Junmei Xu; Ruping Dai; Liang He
Journal:  Ups J Med Sci       Date:  2012-02-03       Impact factor: 2.384

6.  Noradrenaline, Serotonin, GABA, and Glycine in Cerebrospinal Fluid during Labor Pain: A Cross-Sectional Prospective Study.

Authors:  Pornpan Chalermkitpanit; Atikun Thonnagith; Phatthanaphol Engsusophon; Somrat Charuluxananan; Sittisak Honsawek
Journal:  Pain Res Manag       Date:  2017-06-18       Impact factor: 3.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.